News

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
Arboviruses are spreading beyond tropical and subtropical regions owing to climate change, population growth, and increased ...
Vaccine maker Moderna announced today that the US Food and Drug Administration (FDA) has granted full approval of its ...
The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.
Moderna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 ...
The price decline was driven by Moderna's decline and historical data tells us that it's very unlikely for us to see MRNY's price recover from here.
The government’s top vaccine official, working under Health Secretary Robert F. Kennedy Jr., restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists.
He cited similar safety concerns in a May 30 document, entitled “override memo,” regarding wide recommended use of Moderna’s latest version of its mRNA vaccine, mNexspike.
The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use of two Covid-19 vaccines, newly released documents show.